Compare Flagstar Bank NA (FLG) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs GSK plc — how do they compare? Flagstar Bank NA trades at $11.36 (market cap $4.71B), while GSK plc trades at $46.52 (market cap $91.88B). The key difference: GSK plc is far larger — about 19.5× Flagstar Bank NA's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 22 Days and GSK plc for 93 Days on average.
| FLG | GSK | |
|---|---|---|
Market Cap | $4.71B | $91.88B |
Volume | 7,410,589 | 7,730,529 |
Sector | Financials | Health |
52-Week High | $15.36 | $61.18 |
52-Week Low | $10.72 | $43.24 |
Typical Hold Time | 22 Days | 93 Days |
Enterprise Value | $15.25B | $111.88B |
Dividend Yield | 0.35% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Flagstar Bank (FLG) trades at $11.44, up 1.24% with a bearish technical outlook despite recent earnings volatility. The company reported mixed quarterly results with Q2 2026 missing EPS estimates but maintains analyst optimism with a $17.07 consensus target. Fundamentals show improving profitability with net income turning positive in 2026, while valuation metrics present a mixed picture with high P/E but attractive P/B ratio of 0.62.
The stock offers potential upside from current depressed levels given the significant discount to book value and strong analyst buy ratings (60% consensus). Key risks include ongoing earnings volatility, competitive banking pressures, and the challenge of sustaining recent profitability improvements amid economic uncertainty.
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
